Sound Wave Innovation CO., LTD. of Tokyo at MEDICA 2020 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Premium Exhibitor

Sound Wave Innovation CO., LTD.

Ueno Building F6(c-5), 1-9-10, Horidome- Cho Nihonbashi, Chuo-ku, 103-0012 Tokyo

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
JETRO (Japan External Trade Organization)


Kentaro Shiratsuchi



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 01  Electromedical equipment / medical technology
  • 01.03  Surgery devices, endoscopy devices
  • 01.03.12  Other surgical instruments and products

Other surgical instruments and products

  • 01  Electromedical equipment / medical technology
  • 01.04  Therapy and physical medicine
  • 01.04.08  Ultrasonic therapy equipment

Ultrasonic therapy equipment

  • 01  Electromedical equipment / medical technology
  • 01.04  Therapy and physical medicine
  • 01.04.09  Other equipment for therapy and physical medicine

Our products

Product category: Other equipment for therapy and physical medicine

LIPUS (Low Intensity Pulsed Ultlasound)

Indications:Severe angina, dementia, etc.
LIPUS is a brand-new cutting-edge modality and less invasive modality compared to the existing treatment methods. Irradiation of low intensity pulsed ultrasonic waves(250mW, 32 waves) acts on vascular endothelial cells (Caveolin-1) and leads to upregulate both eNOS (vascular endothelial nitric oxide synthase) and VEGF (vascular endothelial growth factor). We expect LIPUS will become an excellent modality for many indications related to microcirculatory disorder.
Regarding severe angina, Prof. Shimokawa’s group developed a low-intensity extracorporeal shock wave device (SW) and that was approved by the Japanese Ministry of Health, Labor and Welfare as advanced medical treatment in 2010. However, there remained some challenges that doctors needs to be careful not to irradiate lungs and take some time to adjust the device.
LIPUS irradiates ultrasonic waves with comaprable output range of echo examinations in health examinations, so it is less invasive and significantly reduces safety risk compared to SW. Prof. Shimokawa’s group discovered LIPUS irradiation conditions that are as effective as SW, and has obtained enough evidence in both basic research and preclinical studies, and the clinical trials have been on going. LIPUS is expected to be applied to mild dementia and other microcirculatory disorder diseases, and it comes to the point only a few years before approval.

More Less

Product category: Other equipment for therapy and physical medicine

Shock Wave Ablation Catheter System (SWCS)

 Indications: Arrhythmias
The number of domestic patients with arrhythmias (ventricular tachycardia (VT) and ventricular fibrillation (Vf)) is estimated to be 5,000 to 11,000 yearly. So far radio frequency ablation catheters(RFCA) are the main existing therapy, but it has several fundamental limitations, including limited ablation depth, thrombus formation, and prolonged inflammation.
SWCS developed by Prof. Shimokawa’s group uses a non-thermal process to converge the shock wave to the arrhythmia source for treatment, so it does not cause damage to the tissue surface and surroundings due to heat, and the depth of ablation can be set larger. It could become a more effective and safer option for arrhythmias

More Less

About us

Company portrait

SWI is a therapeutic medical device startup having strong relationship with Tohoku University(Japan). Making progress on Clinical Studies of both LIPUS and SWCS  (less invasive therapies) that have been developed by Professor Emeritus Hiroaki Shimokawa group, we aim to realize our innovative devices both with Tohoku University and Medical Device Company.

LIPUS(low power pulsed ultrasound)
The molecular mechanisms of the LIPUS therapy include mechano-transduction mediated by β1-integrin/caveolin-1 with resultant upregulation of endothelial NO synthase(eNOs) and vascular endothelial growth factor(VEGF). It enhaces angiogenesis  in ischemic tissue and  induce spontaneous improvement of microcirculatory disorder for both severe angina and mild dementia. Two pipelines are in clinical study.

SWCS(shock wave ablation catheter system)
Comparing to the ablation catheter that has been used for the treatment of arrhythmia, SWCS could treat deeper Arrhythmia source with less surface / peripheral tissues damage and less Thrombus formation.

Company data

Sales volume < 1 Mio US $
Number of employees 1-19
Area of business Imaging and diagnostics / medical equipment & devices

Company information as a PDF file